Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress

October 14, 2016

CAMBRIDGE, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.

“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”

The following posters have been scheduled for presentation:

Number	Poster Title	Presenter	Time
#283	Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break model	Reynald Lescarbeau, Ph.D. Computational Scientist, Bioinformatics	October 19, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET
#280	Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components	David Morrissey, Ph.D. Chief Technology Officer	October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET
#320	DNA repair events after cleavage by CRISPR/Cas9 are not random	Walter Strapps, Ph.D. Senior Director, Biology	October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET
#310	Translating CRISPR/Cas9 genome editing into therapeutics	Tom Barnes, Ph.D. Chief Scientific Officer	October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com

Investor Contacts:

John GrazianoTrout Group
+1 646-378-2942
jgraziano@troutgroup.com

Chad RubinTrout Group
+1 646-378-2947
crubin@troutgroup.com

Intellia Therapeutics, Inc.

Release
Details